Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Care of patients with hepatitis C and HIV co-infection

Soriano, Vincent, Puoti, Massimo, Sulkowski, Mark, Mauss, Stefan, Cacoub, Patrice, Cargnel, Antonietta, Dieterich, Douglas, Hatzakis, Angelos, Rockstroh, Jurgen·2004·AIDS

Abstract

Introduction Liver disease caused by chronic hepatitis C virus (HCV) infection is now a leading cause of morbidity and mortality among HIV-infected patients in the developed world, where classic opportunistic complications of severe immunodeficiency have declined dramatically as a result of the widespread use of potent antiretroviral therapies [1]. Over the past few years, several consensus reports have addressed the issue of viral hepatitis and HIV infection [2,3]. In 2000, a group of experts in the field were invited to join the HCV–HIV International Panel. The first consensus conference took place in Paris [4]. Two years later, the large amount of new information on HCV and HIV, as well as important changes made in the guidelines for using antiretroviral drugs [5], prompted us to organize another consensus conference, which was held in Barcelona in the summer of 2002. Following international recommendations for the development of clinical guidelines [6], the meeting was planned as a full one-day workshop in which nine experts in the field of HIV and viral hepatitis discussed a total of nine questions, which were selected in advance as the most relevant and currently conflicting topics in the management of chronic viral hepatitis in the setting of HIV infection. A draft was written and circulated among panel members during the following months. Finally, in a second meeting that took place in February 2003, a final consensus was reached, and is presented here. The statements are graded according to the Infectious Diseases Society of America scoring system [6], with minor changes (see Table 1).Table 1: Modified Infectious Diseases Society of America scoring system for consensus recommendations.Influence of hepatitis C virus infection on HIV disease progression and response to antiretroviral therapy Background The state of permanent immune activation provided by chronic HCV infection might act deleteriously in HIV-positive individuals, favouring HIV transcription within infected cells and the more rapid destruction of CD4 T lymphocytes [7]. On the other hand, the immune recovery seen after beginning effective antiretroviral therapy could be partly blunted in individuals with HCV infection as a result of similar mechanisms, or through the infection of immune cells by HCV itself [8,9]. Clinical studies that have examined whether there is an influence of HCV on HIV disease progression show conflicting results. Whereas some have demonstrated an association between HCV infection and faster HIV disease progression, others have not [10–30]. In the Swiss cohort [20], HIV-positive individuals with HCV infection progressed faster to AIDS and death than those who were HCV negative. Some of the available data support a direct negative impact of HCV on HIV disease progression, although to a slight extent. In addition, HCV may negatively influence HIV disease in indirect ways, such as making the discontinuation of antiretroviral treatment more frequent because of an increased risk of liver toxicity [4,31]. Panel recommendation HCV might act as a co-factor for HIV disease progression by several mechanisms. First, unspecific immune stimulation driven by chronic HCV infection might enhance HIV replication. Second, the infection of immune cells by HCV could favour CD4 T-cell depletion and partly blunt the immune recovery that follows successful antiretroviral therapy. Third, HCV could compromise the benefit of antiretroviral drugs as a result of a higher incidence of liver toxicity and treatment discontinuation. However, a negative impact of HCV on HIV disease progression has not been recognized in some large clinical-epidemiological studies. SCORE: C.II Candidates for anti-hepatitis C virus treatment Background All HIV-infected individuals should be screened for HCV antibodies in the serum or plasma. HCV-antibody-negative but HCV-RNA-positive cases may exist, mainly in patients with severe cellular immune suppression as a result of HIV [32–34]. Those with repeatedly elevated aminotransferase levels should be tested for HCV load and HCV genotype, in order to assess anti-HCV therapy. All HIV-positive individuals with chronic HCV infection should be considered as candidates for anti-HCV therapy, given their higher risk of progression to end-stage liver disease and their higher risk of liver toxicity after beginning antiretroviral therapy, compared with HIV-negative individuals [4]. As the response to anti-HCV therapy is dependent on the CD4 cell count [35,36], ideally it should be prescribed only when the CD4 cell count is above 350 cells/μl, a threshold that is relatively easy to obtain in most instances when antiretroviral therapy is used properly. Besides, this is currently the immunological cut-off to begin antiretroviral therapy in drug-naive patients [5]. In individuals with CD4 cell counts between 200 and 350 cells/μl, and already under long-term antiretroviral therapy, the decision to treat HCV might be considered takin

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00002030-200401020-00001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 222

Metadata

Authors
Soriano, V., Puoti, M., Sulkowski, M., Mauss, S., Cacoub, P., Cargnel, A., Dieterich, D., Hatzakis, A., & Rockstroh, J.
Venue
AIDS
Published
2004-01
Volume
18
Issue
1
Pages
1-12
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2094883696
Cited by
222
References
1
FWCI
32.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Care of patients with hepatitis C and HIV co-infection. https://app.cochat.ai/papers/10.1097/00002030-200401020-00001
The paper
Soriano, V., Puoti, M., Sulkowski, M., Mauss, S., Cacoub, P., Cargnel, A., Dieterich, D., Hatzakis, A., & Rockstroh, J. (2004). Care of patients with hepatitis C and HIV co-infection. AIDS. https://doi.org/10.1097/00002030-200401020-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.